2022-23 (Round 2) |
Dr Balaji Somasundaram |
Denteric Pty Ltd |
Enabling translation of a therapeutic vaccine candidate against Porphyromonas gingivalis |
National Biologics Facility Queensland Node |
2022-23 (Round 2) |
Ms Reema Bajaj |
Burnet Institute |
Engineering IgG-like ACE2 antivirals against future pathogenic coronavirus events |
National Biologics Facility Queensland Node |
2022-23 (Round 2) |
Professor Fabienne Mackay |
QIMR Berghofer Medical Research Institute |
Large-scale production of a TACI-targeting antibody to test its therapeutic efficacy in a preclinical model of chronic lymphocytic leukaemia. |
Protein Expression Facility |
2022-23 (Round 2) |
Dr Evan Wong |
Lions Eye Institute, Sir Charles Gairdner Hospital and Royal Perth Hospital |
Validation of GMP-compliant manufacture of corneal endothelial cells for intraocular injection as an alternative to corneal transplantation |
Cell & Tissue Therapies WA |
2022-23 (Round 2) |
Associate Professor Joshua Ooi |
Monash University |
Manufacture of autologous T regulatory cells modified ex vivo to express T cell receptors for autoimmune disease |
Centre of Excellence in Cellular Immunotherapy |
2022-23 (Round 2) |
Professor David Ian Roper FRSC |
University of Warwick,UK |
Drug discovery for bacterial glycosyltransferases to combat AMR using the Monash Fragment Platform (MFP) screening facility |
Monash Fragment Platform |
2022-23 (Round 2) |
Associate Professor Ann Kwan |
University of Sydney |
Targeting FtsY for a new class of antibiotics |
Monash Fragment Platform |
2022-23 (Round 2) |
Dr Chengxue Helena Qin |
Monash University |
Novel disease-modifying approach to treat pulmonary hypertension |
Australian Translational Medicinal Chemistry Facility |
2022-23 (Round 2) |
Dr Steven Suchting |
Emenda Therapeutics Australia Pty Ltd |
Development of SRPK1 kinase inhibitors for osteoarthritis pain |
Centre for Drug Candidate Optimisation |
2022-23 (Round 2) |
Dr. William Thomas Jorgensen |
Psylo Pty Ltd and the University of New South Wales |
Understanding the key electronic and structural features for optimal brain penetration of a subset of our novel serotonergic agonists for CNS therapeutic applications |
Centre for Drug Candidate Optimisation |
Technical Feasibility Assessment |
A/Prof Anthony Kicic |
Telethon Kids Institute |
Making bacteriophage therapy a reality: Implementation of a novel treatment pipeline to treat antimicrobial-resistant infections. |
Cell & Tissue Therapies WA |
Technical Feasibility Assessment |
A/Prof Joshua Ooi |
Monash University |
Manufacture of autologous T regulatory cells modified ex vivo to express T cell receptors for autoimmune disease |
Centre of Excellence in Cellular Immunotherapy |
Technical Feasibility Assessment |
Prof Enzo Porrello |
Murdoch Childrens Research Institute |
Evaluating technical feasibility of cGMP production of bioengineered heart tissue to treat heart failure in congenital heart disease |
Centre of Excellence in Cellular Immunotherapy |
Technical Feasibility Assessment |
Dr Rhonda Taylor |
The University of Western Australia (UWA) |
Allele-selective CRISPR deletion as a therapy for ACTA1 congenital myopathy |
Cell & Tissue Therapies WA |
Technical Feasibility Assessment |
Dr Evan Wong |
Royal Perth Hospital |
Validation of GMP-compliant manufacture of corneal endothelial cells for injection |
Cell & Tissue Therapies WA |
2022-23 (Round 1) |
Prof Philip Board |
Omega-One Therapeutics Pty. Ltd. |
Developing Glutathione transferase Omega 1 inhibitors as anti-inflammatory therapeutics |
Australian Translational Medicinal Chemistry Facility |
2022-23 (Round 1) |
Prof Enzo Porrello |
Murdoch Children’s Research Institute |
Developing next generation cardio-regenerative therapeutics to treat systolic heart failure |
Australian Translational Medicinal Chemistry Facility |
2022-23 (Round 1) |
Dr Richard Foitzik |
Oncology One Pty Ltd |
ADME investigation into methyltransferase inhibitor candidates |
Centre for Drug Candidate Optimisation |
2022-23 (Round 1) |
Ms Filippa Shub |
Inosi Therapeutics |
IRAP inhibitor lead optimisation |
Centre for Drug Candidate Optimisation |
2022-23 (Round 1) |
Prof Mark von Itzstein |
Institute for Glycomics, Griffith University |
Development of drug candidates against drug resistant bacteria |
Centre for Drug Candidate Optimisation |
2022-23 (Round 1) |
Prof Brian Gabrielli |
Mater Research Institute |
Screen for compounds synthetically lethal with defective RB and p53 |
Discovery Biology Griffith |
2022-23 (Round 1) |
Mr Robert Batchelor |
Nutromics Pty Ltd |
Surface plasmon resonance-based screening of DNA aptamers targeted to small molecule drugs |
Monash Fragment Platform |
2022-23 (Round 1) |
Dr Jacek Kwiatkowski |
Queensland Emory Drug Discovery Initiative |
Identification of Inhibitors of a Key Necroptotic Protein Through Fragment Screening |
Monash Fragment Platform |
2022-23 (Round 1) |
Prof Alastair Stewart |
University of Melbourne |
Discovery of selective inhibitors for fibrosis |
Monash Fragment Platform |
2022-23 (Round 1) |
Mr Paul Fahey |
Vaxxas Pty. Ltd. |
Enhanced skin delivery of vaccines by manipulating surface interactions on High Density Micro Array Patches (HD-MAP’s). |
National Biologics Facility Victoria Node |
2022-23 (Round 1) |
A/Prof Daniel Thomas |
University of Adelaide |
Anti-mutant CALR Antibody Preparation for Clinical Manufacture for Patients with Myelofibrosis |
National Biologics Facility Queensland Node |
2022-23 (Round 1) |
Dr Graham Heery |
Starpharma Pty Ltd |
Production of a HER2 binding nanobody for the assembly of targeted novel dendrimer therapeutics for breast and gastric cancer |
Protein Expression Facility |
2022-23 (Round 1) |
Prof James St John |
Griffith University |
Spinal Injury Project: pilot-scale GMP production and validation of clinically compliant nerve bridges |
Q-Gen Cell Therapeutics |
2022-23 (Round 1) |
Dr Steve Dingwall |
Australian Institute for Bioengineering and Nanotechnology |
Generation of Induced Pluripotent Stem Cell Master and Working Cell Banks for a Phase 1 Clinical Trial for the Treatment of Heart Failure |
Q-Gen Cell Therapeutics |
2022-23 (Round 1) |
Prof Andrew Elefanty |
Murdoch Children’s Research Institute |
Building a better leukaemia – Modeling paediatric acute myeloid leukaemia in pluripotent stem cells |
Stafford Fox Disease Modelling Facility |
2022-23 (Round 1) |
A/Prof Silvia Velasco |
Murdoch Children’s Research Institute |
Development of a platform for the automated generation and high-throughput drug screening of brain organoids |
Stafford Fox Disease Modelling Facility |
2022-23 (Round 1) |
Prof Robyn Jamieson |
Children’s Medical Research Institute |
Long-term AAV-mediated genetic rescue of photoreceptors in retinitis pigmentosa |
Sydney Cell and Gene Therapies |
2022-23 (Round 1) |
A/Prof James Chong |
Westmead Institute for Medical Research |
Process development for the preparation and delivery of induced pluripotent stem cell derived cardiomyocytes for end stage heart failure. |
Sydney Cell and Gene Therapy |
2022-23 (Round 1) |
A/Prof Elaine Sanij |
St Vincent’s Institute of Medical Research |
Development of new cancer therapeutics targeting the nucleoli |
Victorian Centre for Functional Genomics |
2021-22 (Round 2) |
Prof Christopher Langmead |
Monash Institute of Pharmaceutical Sciences |
Development of novel agonists for schizophrenia |
Australian Translational Medicinal Chemistry Facility |
2021-22 (Round 2) |
Prof Roland Stocker |
Heart Research Institute |
Synthesis of a novel PET probe to detect plaque activity for the identification of high-risk atherosclerosis |
Australian Translational Medicinal Chemistry Facility |
2021-22 (Round 2) |
Dr Thomas Theodor Tapmeier |
Monash University |
NPSR1 Antagonist in Endometriosis |
Australian Translational Medicinal Chemistry Facility |
2021-22 (Round 2) |
Prof Ian Smyth |
Monash University |
Pharmacokinetic assessment and optimisation of a new therapy for PKD |
Australian Translational Medicinal Chemistry Facility and Centre for Drug Candidate Optimisation |
2021-22 (Round 2) |
A/Prof Ethan D. Goddard-Borger |
Walter and Eliza Hall Institute of Medical Research |
Development of anthelmintics with a novel mode of action |
Centre for Drug Candidate Optimisation |
2021-22 (Round 2) |
Dr William Thomas Jorgensen |
Psylo Pty Ltd |
Pre-clinical development of novel serotonergic agents for therapeutic applications in mental illness |
Centre for Drug Candidate Optimisation |
2021-22 (Round 2) |
Dr Sohinee Sarkar |
Murdoch Children’s Research Institute |
A new treatment for the cystic fibrosis superbug, Mycobacteroides abscessus |
Compounds Australia |
2021-22 (Round 2) |
Dr Nicole Van Bergen |
Murdoch Children’s Research Institute |
Utilising high-throughput drug screening for mitochondrial metabolite repair disorders |
Compounds Australia |
2021-22 (Round 2) |
Dr Katherine Locock |
CSIRO |
Accelerated antibiotic discovery through high-throughput |
Compounds Australia and Community for Open Antimicrobial Drug Discovery |
2021-22 (Round 2) |
A/Prof Rebecca Lim |
Prescient Therapeutics |
Preclinical toxicity studies for OmniCAR-enabled targeting ligands |
National Biologics Facility Queensland Node |
2021-22 (Round 2) |
Prof Kristen Radford |
Mater Research Institute |
Development of human CLEC9A antibodies as cancer vaccines |
National Biologics Facility Queensland Node |
2021-22 (Round 2) |
Dr Sarah Jones |
Monash University |
A novel Glucocorticoid (GC) mimic for the treatment of inflammatory and autoimmune diseases |
National Biologics Facility Victoria Node |
2021-22 (Round 2) |
A/Prof Rebecca Lim |
Hudson Institute of Medical Research |
Phase II Amnion Cell Therapy in Ischemic Stroke |
Q-Gen Cell Therapeutics |
2021-22 (Round 2) |
Prof Timothy Stinear |
University of Melbourne |
A high-throughput screening campaign to find inhibitors of intracellular multi-drug resistant Staphylococcus aureus |
Victorian Centre for Functional Genomics |
2021-22 (Round 2) |
A/Prof Kara Britt |
Peter MacCallum Cancer Centre |
Identify drugs that selectively inhibit oestrogen receptor positive luminal progenitor activity |
Victorian Centre for Functional Genomics |
2021-22 (Round 1) |
Prof Ian Smyth |
Monash University |
Inhibiting cyst formation in polycystic kidney disease with targeted protein degraders (TPDs) |
Australian Translational Medicinal Chemistry Facility |
2021-22 (Round 1) |
A/Prof Nick Clemons |
Peter MacCallum Cancer Centre |
Synthesis of novel small molecule inhibitors of SLC7A11/XCT for mutant-p53 cancers |
Australian Translational Medicinal Chemistry Facility |
2021-22 (Round 1) |
Dr Robert Feldman |
COVID-19 Vaccine Corporation |
Development of an mRNA cytotoxic T-cell COVID-19 vaccine |
BASE Facility |
2021-22 (Round 1) |
Dr Willem Joost Lesterhuis |
Telethon Kids Institute |
Development of small molecule drugs in immuno-oncology |
Centre for Drug Candidate Optimisation |
2021-22 (Round 1) |
A/Prof Jonathan S. Oakhill |
St Vincent’s Institute of Medical Research |
Development of CaMKK2 inhibitors as new cancer therapies |
Centre for Drug Candidate Optimisation |
2021-22 (Round 1) |
Dr Samantha South |
Argenica Therapeutics Ltd |
Neuroprotective efficacy of poly-argine-18 (R18) in a relapsing-remitting experimental autoimmune encephalomyelitis (RR-EAE) mouse model of multiple sclerosis (MS) |
Centre for Integrated Preclinical Drug Development |
2021-22 (Round 1) |
Dr Ben Rollo |
Monash University |
Human high-throughput in-vitro phenotypic screening for new epilepsy drugs |
Compounds Australia |
2021-22 (Round 1) |
Prof Sudha Rao |
QIMR Berghofer |
Identification of a small molecule inhibitor for therapeutic targeting of a novel nuclear methyltransferase in immunotherapy-resistant metastatic cancers |
GRIDD Mass Spectrometry Screening |
2021-22 (Round 1) |
A/Prof Jenny Gunnersen |
University of Melbourne |
Screening for therapeutic antibodies to treat chronic pain |
National Biologics Facility Queensland Node |
2021-22 (Round 1) |
Prof John Hooper |
Mater Research Institute |
Process development to optimise and characterise the conjugation process of DFO and monoclonal antibody 10D7 |
National Biologics Facility Victoria Node |
2021-22 (Round 1) |
Dr Nicholas Hunt |
University of Sydney |
Synthesis and characterisation of Ag2S quantum dots and conjugation to insulin at CSIRO |
National Biologics Facility Victoria Node |
2021-22 (Round 1) |
Dr Chisha Teza Sikazwe |
PathWest Laboratory Medicine WA |
Development of recombinant MVEV and JEV NS1 antigen for the detection of JEV and MVEV antibody in serum |
Protein Expression Facility |
2021-22 (Round 1) |
Prof Rajiv Khanna |
QIMR Berghofer |
The establishment of a repository of in vitro-expanded cytomegalovirus-specific T cells for the treatment of glioblastoma multiforme |
Q-Gen Cell Therapeutics |
2021-22 (Round 1) |
Prof John EJ Rasko |
Centenary Institute |
Novel gene therapy platforms for hemophilia B |
Vector and Genome Engineering Facility |
2021-22 (Round 1) |
Dr Gonzalo Perez-Siles |
ANZAC Research Institute |
Development of a high throughput screening platform of patient-derived iPSC motor neuron for enhancers of energy metabolism as a therapeutic intervention in axonal degeneration |
Victor Chang Cardiac Research Institute |
2021-22 (Round 1) |
Dr Marie Besnier |
University of Sydney |
Treating the mitochondria to improve endothelial function of patients with coronary artery disease |
Victor Chang Cardiac Research Institute |
2021-22 (Round 1) |
Dr Mitchell Lawrence |
Monash University |
New generation combination therapies for advanced prostate cancer |
Victorian Centre for Functional Genomics |
2020-21 (Round 2) |
Dr Chengxue Helena Qin |
Monash University |
Next generation formyl peptide receptor 2 agonists to treat pulmonary hypertension |
Australian Translational Medicinal Chemistry Facility |
2020-21 (Round 2) |
Dr Mitali Sarkar-Tyson |
University of Western Australia |
Advanced development of therapeutics against bacterial pathogens of biowarfare concern |
Australian Translational Medicinal Chemistry Facility |
2020-21 (Round 2) |
A/Prof Daniel Thomas |
University of Adelaide |
Iterative design of selective Type II JAK2 Inhibitor for superior management of myelofibrosis |
Australian Translational Medicinal Chemistry Facility |
2020-21 (Round 2) |
Dr Nadia Warner |
Peter Doherty Institute for Infection and Immunity |
Synthesis and development of targeted degraders of the hepatitis B virus (HBV) core proteins for HBV therapy |
Australian Translational Medicinal Chemistry Facility |
2020-21 (Round 2) |
Dr Mark Devlin |
Aculeus Therapeutics Pty Ltd |
Systemically delivered small molecule STING agonists as next generation cancer immunotherapies |
Centre for Drug Candidate Optimisation |
2020-21 (Round 2) |
Dr Paul Stupple |
CTx/Monash University |
In vivo and in vitro pharmacokinetic studies of novel therapeutics against blood cancers |
Centre for Drug Candidate Optimisation |
2020-21 (Round 2) |
Dr Chris Langmead |
Monash University |
Development of biased agonists for schizophrenia |
Centre for Drug Candidate Optimisation and Australian Translational Medicinal Chemistry Facility |
2020-21 (Round 2) |
Dr Pegah Varamini |
University of Sydney |
Development of novel therapeutics for targeted therapy of triple negative breast cancer |
Centre for Integrated Preclinical Drug Development |
2020-21 (Round 2) |
Dr Julian Barden |
Biosceptre Aust Pty Ltd |
Development of novel cellular cancer therapeutics |
National Biologics Facility NSW Node |
2020-21 (Round 2) |
A/Prof Ashley Buckle |
Monash University |
Development of novel anti-inflammatory biologics |
National Biologics Facility Queensland Node |
2020-21 (Round 2) |
Prof Elizabeth Coulson |
University of Queensland |
Therapeutic antibody discovery to block neurotrophin receptor cleavage |
National Biologics Facility Queensland Node |
2020-21 (Round 2 – Screening) |
A/Prof Ian Street |
Children’s Cancer Institute |
Development of an assay system to identify CNS-penetrant derivatives of pre-existing drugs for brain cancer |
ACRF Drug Discovery Centre |
2020-21 (Round 2 – Screening) |
Prof Klaus-Martin Schulte |
Australian National University |
Identifying therapeutics for the treatment of advanced BRCA2 breast cancer” |
ANU Centre for Therapeutic Discovery |
2020-21 (Round 2 – Screening) |
Prof Mark Dawson |
Peter MacCallum Cancer Centre |
Identification of novel immune-checkpoint therapies to inhibit interaction between PD-L1 and CMTM6, a new regulator of anti-tumour immunity |
Discovery Biology |
2020-21 (Round 2 – Screening) |
Dr Jess Tiffen |
Centenary Institute |
Identifying Epigenetic Drivers of Drug Resistant Melanoma |
Discovery Biology |
2020-21 (Round 2 – Screening) |
A/Prof Ethan D. Goddard-Borger |
WEHI |
Developing fucosyltransferase inhibitors as treatments for rare leukaemia |
Monash Fragment Platform |
2020-21 (Round 2 – Screening) |
Dr Ueli Nachbur |
WEHI |
Identification of small molecule binders to Deubiquitinases |
Monash Fragment Platform |
2020-21 (Round 2 – Screening) |
Prof Frederic Hollande |
University of Melbourne |
Developing a combined small molecule and immune cell killing assay to identify new therapeutics in pancreatic cancer” |
Victorian Centre for Functional Genomics |
2020-21 (Round 1) |
Dr Mark Del Borgo |
Monash University |
Synthesis of novel peptide mimics for use as anti-fibrotic agents |
Australian Translational Medicinal Chemistry Facility |
2020-21 (Round 1) |
Prof. Ian Smyth |
Monash University |
Inhibiting cystogenesis in Polycystic Kidney Disease with AURKA PROTACs |
Australian Translational Medicinal Chemistry Facility |
2020-21 (Round 1) |
Dr. Christopher Burns |
MycRx Pty Ltd |
Novel, small-molecule therapeutics for the treatment of cancers addicted to the oncoprotein Myc |
Centre for Drug Candidate Optimisation |
2020-21 (Round 1) |
Prof. Alastair Stewart |
Tianli Biotech Pty Ltd |
Development of casein kinase 1 delta inhibitors for inflammation, fibrosis and fibrotic cancers |
Centre for Drug Candidate Optimisation |
2020-21 (Round 1) |
Dr. Fernando S. F. Guimaraes |
University of Queensland |
Development of new anti-breast cancer antibodies for natural killer (NK) cell-based immunotherapy |
National Biologics Facility Queensland Node |
2020-21 (Round 1) |
Prof. John Hooper |
Mater Research Institute |
Production and Stability Study of 5 variants of 10D7 antibody |
National Biologics Facility Queensland Node |
2020-21 (Round 1) |
Prof. Alex Loukas |
James Cook University |
Innovative IBD biologics inspired by host-parasite coevolution |
National Biologics Facility Queensland Node |
2020-21 (Round 1) |
Prof. Peter Timms |
University of Sunshine Coast |
Development of a chlamydial vaccine for koalas: Production of chlamydial proteins at high quality suitable for vaccine trials |
National Biologics Facility Victoria Node |
2020-21 (Round 1) |
Dr. Brad Walsh |
Glytherix Ltd |
Optimisation and Characterisation of Miltuximab-DFO Bioconjugation |
National Biologics Facility Victoria Node |
2020-21 (Round 1) |
Prof. Andrew Prowse |
University of Queensland |
Pilot scale GMP production of cardiomyocytes derived from human pluripotent stem cells |
Q-Gen Cell Therapeutics |
2020-21 (Round 1) |
Dr Stuart Fraser |
University of Sydney |
Nanions: a rapid, non-toxic nanoparticle vaccine platform |
TetraQ |
2020-21 (Round 1) |
Prof. Suddha Rao |
QIMR Berghofer Medical Research Institute |
Safety and pharmacokinetics study of a novel anti-PD-L1 therapeutic to improve immunotherapy in triple-negative breast cancer |
TetraQ |
2020-21 (Round 1) |
Prof. Mark von Itzstein |
Griffith University |
Preclinical development of a drug lead candidate against human parainfluenza virus – Exploratory pharmacokinetic, toxicity, and metabolic studies |
TetraQ and Centre for Drug Candidate Optimisation |
2020-21 (Round 1 – Screening) |
Prof. Ian Street |
Children’s Cancer Institute |
Development of a high-throughput screening assay for a novel activated kinase ALPK1 |
ACRF Drug Discovery Centre |
2020-21 (Round 1 – Screening) |
A/Prof Marco Casarotto |
Australian National University |
Developing therapeutics that treat/prevent ischemia reperfusion injury (IRI) |
ANU Centre for Therapeutic Discovery |
2020-21 (Round 1 – Screening) |
Assoc. Prof. Leonie Quinn |
Australian National University |
High-Throughput 3D Cell and Organism Screening for new brain cancer (glioma) treatments |
ANU Centre for Therapeutic Discovery |
2020-21 (Round 1 – Screening) |
Prof. Sally-Ann Poulsen |
Griffith University |
Restoring the efficacy of chemotherapy in drug resistant cancers |
Discovery Biology |
2020-21 (Round 1 – Screening) |
Prof. Murray Whitelaw |
University of Adelaide |
Discovery and development of new antimicrobials to combat antibiotic resistance |
GRIDD Mass Spectrometry Screening Platform |
2020-21 (Round 1 – Screening) |
Dr Shom Goel |
Peter MacCallum Cancer Centre |
Improving outcomes for breast cancer patients receiving CDK4/6 inhibitors |
Victorian Centre for Functional Genomics |
2020-21 (Round 1 – Screening) |
Dr. Eleanor Saunders |
University of Melbourne |
Targeting human leishmaniasis |
Victorian Centre for Functional Genomics |
COVID-19 (2020) |
Dr Arun Konagurthu |
Monash University |
Modelling, synthesis and testing of potential agents against COVID-19 main protease |
Australian Translational Medicinal Chemistry Facility |
COVID-19 (2020) |
Dr Charles Bailey |
Centenary Institute |
Monitoring the therapeutic efficacy of BD-218, a human neutralising monoclonal antibody against SARS-CoV-2, in COVID-19 patients using Nanostring gene expression analysis |
Cell & Molecular Therapies, Royal Prince Alfred Hospital |
COVID-19 (2020) |
Prof Bevyn Jarrott |
Vailima Peninsula Pty Ltd |
Pre-clinical development of a novel, patented small molecule to treat COVID-19 respiratory injury |
Centre for Drug Candidate Optimisation |
COVID-19 (2020) |
Dr Richard Angell |
University College London |
Using fragment-based drug discovery to identify small molecule inhibitors of SARS-CoV-2 (COVID-19) RNA-dependent RNA polymerase (RdRp) and future starting points for other Coronaviruses |
Monash Fragment Platform |
COVID-19 (2020) |
Prof John Hayball |
Sementis Ltd/UniSA |
Large-scale manufacture of the Sementis Copenhagen Vector (SCV) COVID-19 vaccine |
National Biologics Facility Victoria Node |
COVID-19 (2020) |
Prof Terrance Johns |
Telethon Kids Institute |
Discovery of antibodies to the furin cleavage site of SARS-CoV-2 Spike Glycoprotein |
National Biologics Facility Queensland Node |
COVID-19 (2020) |
A/Prof Severine Navarro |
QIMR Berghofer Medical Research Institute |
Prevention of COVID-19-induced hyperinflammatory syndrome with the immunomodulatory protein AIP-2” |
National Biologics Facility Queensland Node |
COVID-19 (2020) |
Dr Keith Dredge |
Zucero Therapeutics Ltd |
Analytical and bioanalytical development of pixatimod (ZU545/PG545)- a clinical candidate for cancer with anti-viral and anti-inflammatory properties – to support clinical testing for Covid-19” |
TetraQ |
COVID-19 (2020) |
Dr Cameron Stewart |
Australian Centre for Disease Prevention (ACDP), CSIRO |
Defining the role of host microRNAs in COVID-19” |
Victorian Centre for Functional Genomics |
2019-20 (Screening) |
Prof Brian Gabrielli |
TRI |
Screen for new agents to selectively kill a novel defect in melanomas |
ACRF Drug Discovery Centre |
2019-20 (Screening) |
Dr Joseph Brock |
ANU |
Development of an engineered thermal shift assay for the high-throughput discovery of integral membrane protein lead compounds |
ANU Centre for Therapeutic Discovery |
2019-20 (Screening) |
Dr Amee George |
ANU |
Identifying therapeutics for the treatment of Myelodysplastic Syndrome |
ANU Centre for Therapeutic Discovery |
2019-20 (Screening) |
Prof Si Ming Man |
ANU |
Novel antitoxin compound discovery for the treatment of antibiotic resistant bacteria |
ANU Centre for Therapeutic Discovery |
2019-20 (Screening) |
Dr Nicholas Eyre |
University of Adelaide |
Development of inhibitors of dengue virus (DENV) NS1 protein dimerization as novel antiviral therapeutics |
Cell Screen SA |
2019-20 (Screening) |
Dr Benjamin Blasco |
GARDP |
The discovery and development of novel antibiotics against MDR and XDR Gram-negative pathogens |
CO-ADD |
2019-20 (Screening) |
Ms Natasa Broit |
QIMR Berghofer |
Identification of novel therapies for the treatment of acral lentiginous melanoma |
Griffith Discovery Biology |
2019-20 (Screening) |
Dr Brian Dymock |
UniQuest |
Identification of Inhibitors of a key oncogenic protein by Fragment Screening |
Monash Fragment Platform |
2019-20 (Screening) |
Dr Dane Cheasley |
Peter MacCallum Cancer Institute |
High throughput investigation of synergistic drug combinations for patients with low-grade serous ovarian carcinoma |
Victorian Centre for Functional Genomics |
2019-20 (Screening) |
Dr Nicholas Clemons |
Peter MacCallum Cancer Institute |
A specific inhibitor of SLC7A11 (XCT) for single agent or combination treatment of cancers with mutant p53 |
Victorian Centre for Functional Genomics |
2019-20 (Screening) |
Dr Kathleen Pishas |
Peter MacCallum Cancer Institute |
Defining the role of clonal interaction in high grade serous ovarian cancer drug resistance |
Victorian Centre for Functional Genomics |
2019-20 (Screening) |
Dr Michael Sharp |
St. Vincent’s Institute of Medical Research |
Inhibiting the Fanconi Anaemia pathway to target BRCA1/2 negative breast and ovarian cancers |
Victorian Centre for Functional Genomics |
2019-20 (Core facilities) |
Dr David Elliott |
Murdoch Children’s Research Institute |
Identifying compounds that protect against anthracycline induced heart damage |
Australian Translational Medicinal Chemistry Facility |
2019-20 (Core facilities) |
Prof Tom Gonda |
University of South Australia |
Development of a small molecule inhibitor of the MYB oncogene as a therapeutic for Acute Myeloid Leukaemia |
Australian Translational Medicinal Chemistry Facility |
2019-20 (Core facilities) |
Dr Steven Petratos |
Monash University |
Development of Small Molecules to Promote Remyelination in Multiple Sclerosis |
Australian Translational Medicinal Chemistry Facility |
2019-20 (Core facilities) |
Mr Gregory Santamaria |
Cyclotek (Aus) Pty Ltd |
Development of advanced and novel radioligands for Positron Emission Tomography (PET) imaging |
Australian Translational Medicinal Chemistry Facility |
2019-20 (Core facilities) |
Prof Katherine Andrews |
Griffith Institute for Drug Discovery (GRIDD) |
Pre-clinical optimisation studies on a new antimalarial drug lead |
Centre for Drug Candidate Optimisation |
2019-20 (Core facilities) |
Dr Ebony Fietz |
Gertrude Biomedical Pty Ltd |
Preclinical ADME and PK drug properties of novel inhibitors of SOX18 transcription factor |
Centre for Drug Candidate Optimisation |
2019-20 (Core facilities) |
Dr Wim Meutermans |
Vast Bioscience Pty Ltd |
ADME and PK evaluation of VAST preclinical candidates for postsurgical pain |
Centre for Drug Candidate Optimisation |
2019-20 (Core facilities) |
Prof Bernard Flynn |
Monash University |
Targeting Sphingosine Kinase 1 for the Treatment of Pulmonary Hypertension |
Centre for Drug Candidate Optimisation and TetraQ |
2019-20 (Core facilities) |
Dr Nicholas Veldhuis |
Monash University |
Assessing efficacy of analgesic nanoparticles in chemotherapy-induced neuropathic pain |
Centre for Integrated Preclinical Drug Development |
2019-20 (Core facilities) |
A/Prof Brendon Coventry |
Cancuravax Pty Ltd |
Melanoma Cancer Vaccine Immunotherapy Production & Scaling for Commercialisation |
National Biologics Facility NSW Node |
2019-20 (Core facilities) |
Dr Brad Walsh |
GlyTherix Ltd |
Production and Lead Selection of Humanised Anti-Glypican-1 Antibodies |
National Biologics Facility NSW Node |
2019-20 (Core facilities) |
Kevin Isch |
NeuClone Pty Ltd |
Development and validation of an ECL immunoassay method for quantitation of ustekinumab concentration in human serum (TetraQ Study Code NEU-005); Quantification of ustekinumab concentration in human serum samples (TetraQ Study Code NEU-006); Development and validation of an ECL immunoassay method for detection of ustekinumab anti-drug antibody (ADA) response in human serum (TetraQ Study Code NEU-007); Analysis of serum samples for ustekinumab ADA response (TetraQ Study Code NEU-008) |
TetraQ |
2017-18 |
Dr Christopher J Burns |
Metabloq Pty Ltd |
High Throughput Screening of Compound Libraries against a Novel Cancer Metabolism Drug Target |
ACRF Drug Discovery Centre for Childhood Cancer |
2017-18 |
Dr Glen Carter |
Peter Doherty Institute/ BioCurate |
Development of Novel Gut-Targeted Antibiotics for the Treatment of Multidrug-Resistant Pathogens |
Australian Translational Medicinal Chemistry Facility |
2017-18 |
Prof. Spencer Williams |
University of Melbourne |
Pharmacokinetics and distribution of novel non-steroidal asthma drugs |
Centre for Drug Candidate Optimisation |
2017-18 |
Dr Guy Krippner |
Baker IDI |
Novel Receptor Agonists for difficult to treat chronic illness |
Centre for Drug Candidate Optimisation and Australian Translational Medicinal Chemistry Facility |
2017-18 |
Dr Susie Nilson |
CSIRO |
Toxicology and pharmacokinetic profiling of a stem cell mobilisation agent |
Centre for Drug Candidate Optimisation and TetraQ |
2017-18 |
Dr Natalie Borg |
Monash University |
A broad-spectrum antiviral target and anticancer target |
Compounds Australia |
2017-18 |
Prof. Charles Mackay |
Monash University |
Developing an agonistic antibody |
Monash Antibody Technologies Facility |
2017-18 |
Prof. Rajiv Khanna |
QIMR Berghofer |
The establishment of a repository of in vitro-expanded T cells for the treatment of viral complications in transplant recipients |
Q-Gen Cell Therapies |